Cellvizio® is the real-time in vivo cellular imaging platform that is an adjunct to the standard of care and enables physicians to detect and monitor the progression of GERD to Barrett’s Esophagus (BE) over time using proprietary advanced imaging technology.
Barrett's Esophagus is the only known precursor of Esophageal Adenocarcinoma (EAC).1
Based on the growing prevalence of BE and EAC among patients, it is obvious that inadequate surveillance of the esophagus with standard biopsy techniques leads to missed diagnoses of dysplasia and EAC altogether, casting doubt on the role of surveillance endoscopy as it is today.5
The Seattle Protocol, or gold standard for index endoscopy procedures, calls for 4-quadrant biopsies every 1 to 2 centimeters. Even if adhered to, the Seattle Protocol proves to have lower detection rates of dysplasia due to the irregularity and complexity of esophageal tissue, suggesting that this systematic approach alone to identifying random islands of dysplasia is insufficient.5
With Cellvizio as an adjunct to Seattle protocol, physicians have clear, minimally invasive visualization of the esophagus at the cellular level to obtain a comprehensive assessment of the extent of disease and make real-time therapeutic decisions.
Cellvizio® Clinical Value
Cellvizio is powered by a technology known as probe-based confocal laser endomicroscopy, or pCLE, which allows for visibility of cell architecture at the microscopic level. Compared to the standard, random biopsy protocol alone, the addition of Cellvizio as an adjunct technology doubles the detection rate of Barrett's Esophagus6, where 1.7 times more lesions were detected with Cellvizio and WLE when compared to WLE and NBI alone7,8. When compared to WLE random biopsies, Cellvizio provides a significantly higher diagnostic yield and accuracy with reduced sampling error.5,7
Cellvizio advanced imaging and its easy integration into existing workflows allows physicians to better target biopsies within focused areas of concern, augmenting conventional technologies and techniques, and improving the ability to detect and monitor cellular changes.
For surgeons, this technology has the potential to reduce inappropriate endoluminal therapy for non-neoplastic conditions, thus improving overall procedure-related complications, optimizing surveillance intervals, and limiting histological analysis of insignificant lesions.12 This helps improve diagnostic yield and increase the detection of dysplastic lesions from 34% to 68%.7
Cellvizio® is part of routine clinical practice
See how Dr. Joseph Burnette, a general surgeon with special interest in reflux uses Cellvizio® on all his chronic reflux patients.
"Cellvizio® adds 3-5 minutes, while more than doubling detection of Barrett's Esophagus vs. conventional biopsies."
Dr. A. McNair Jr., New Gulf Coast Surgery Center
using Cellvizio® GastroFlex UHD Miniprobe
Criteria: squamous epithelium with flat and scale-like cells, intrapapillary loops
Criteria: regular columnar-lined epithelium, dark mucin in goblet cells easily identified, equidistant and regular cells, glands equal in size and shape
Criteria: epithelial surface appearing saw-toothed, non equidistant glands, glands unequal in size and shape, pleomorphic and enlarged cells
Cellvizio® leads to better informed patient management by providing additional advanced imaging, enabling real-time tissue assessment and early detection. Physicians are able to rule-in or rule-out intestinal metaplasia in the presence of GERD symptoms9, allowing for earlier detection of BE6 and the monitoring of such disease.7,8
Physicians also are able to define the location and lateral extent of neoplasia inducing clinical intervention10, as well as differentiate lesions that are not amenable to EMR and determine the margins of a lesion before endoscopic resection12. Therefore, pCLE can lead to positive redirection of therapy.11
Adding Cellvizio as an adjunct to EGD provides physicians the unique ability to obtain an earlier, more accurate diagnosis and inform real-time therapeutic decisions. As a result, tailored treatment plans that are specific to the patient’s needs offer economic benefits in terms of patient timeline and resource utilization.
According to an abstract presented in 2022 at WorldEndo, as seen in the chart, "The use of Cellvizio is associated with lower health services utilization of endoscopy, anesthesia, biopsy, ablation, and brush cytology."13
Cellvizio enables physicians to assess areas of concern and target biopsies for increased diagnostic yield, optimizing utilization of health service resources and reducing overall number of unnecessary endoscopy procedures required for diagnosis and treatment.13
- Bhardwaj A. et al. Barrett’s Esophagus: Emerging Knowledge and Management Strategies. Pathology Research International, 2012. doi: 10.1155/2012/814146.
- Chai J. et al. Esophageal malignancy: A growing concern, World Journal of Gastroenterology, 2012. doi: 10.3748/wjg.v18.i45.6521.
- Desai M. et al. Prevalence of HGD and adenocarcinoma on index endoscopy in BE, Gastrointest Endosc, 2018. doi: 10.1016/j.gie.2018.09.041.
- Visrodia K. et al. Magnitude of Missed Esophageal Adenocarcinoma After Barrett’s Esophagus Diagnosis: A Systematic Review and Meta-analysis. Gastroenterology, 2016. doi: 10.1053/j.gastro.2015.11.040.
- DeMeester S. et al. High definition probe-based confocal laser endomicroscopy review and meta-analysis for neoplasia detection in Barrett's esophagus. Techniques and Innovations in Gastrointestinal Endoscopy, 2022. doi: 10.1016/j.tige.2022.06.001.
- Richardson C. et al. Real-time diagnosis of Barrett’s Esophagus: a prospective, multicenter study comparing confocal laser endomicroscopy with conventional histology for the identification of intestinal metaplasia in new users, Surgical Endoscopy, 2018. doi: 10.1007/s00464-018-6420-9.
- Sharma P. et al. Real-time increased detection of Neoplastic tissue in Barrett’s Esophagus with pCLE; Final results of a multi-center prospective international randomized controlled trial, Gastrointest Endosc, 2011. doi: 10.1016/j.gie.2011.04.004.
- Canto M. et al. In vivo endomicroscopy improves detection of Barrett’s Esophagus related neoplasia: a multicenter international randomized controlled trial, GIE, 2013. doi: 10.1016/j.gie.2013.09.020.
- Kiesslich R. et al. In vivo histology of Barrett’s Esophagus and Associated Neoplasia by CLE, Clinical Gastro and Hepatology, 2006.
- Wang K. et al. Use of probe-based confocal laser endomicroscopy (pCLE) in gastrointestinal applications. A consensus report based on clinical evidence. UEGW Journal, 2015. doi: 10.1177/2050640614566066.
- Caillol et al. Probe confocal laser endomicroscopy in the therapeutic endoscopic management of Barrett’s dysplasia. Annals of Gastroenterology, 2017. doi: 10.20524/aog.2017.0138.
- Al-Mansour. et al. SAGES TAVAC safety and efficacy analysis confocal laser endomicroscopy. Surg Endosc, 2020. doi: 10.1007/s00464-020-07607-3.
- Randhawa N, et al. P390 Health service utilization among patients with Barrett's Esophagus using confocal laser endomicroscopy versus standard of care. World Endo 2022 Poster session. https://endo2022.abstractserver.com/program/#/details/presentations/462